

Renal Replacement Therapy

Adults:

→ *Dose in patients undergoing renal replacement therapy:*

Hemodialysis, intermittent (thrice weekly): Not dialyzable.

Peritoneal dialysis: Not dialyzable. ^[1]

CRRT: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Dose as in $\text{eGFR} < 25 \text{ mL/minute/1.73 m}^2$, as removal by CRRT is expected to be insignificant. ^[2]

PIRRT (eg, sustained, low-efficiency diafiltration): Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Dose as in $\text{eGFR} < 25 \text{ mL/minute/1.73 m}^2$, as removal by PIRRT is expected to be insignificant ^[2]

Pediatrics:

→ *Dose in patients undergoing renal replacement therapy:*

Hemodialysis: Supplemental dose is not necessary.

Peritoneal dialysis: Supplemental dose is not necessary

[1] - MacPhee IA, Spreafico S, Bewick M, et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. *Kidney Int.* 2000;57(3):1164-1168. doi:10.1046/j.1523-1755.2000.00943.x[PubMed 10720968]

[2]- Cussonneau X, Bolon-Larger M, Prunet-Spano C, Bastien O, Boulieu R. Evaluation of MPA and MPAG removal by continuous venovenous hemodiafiltration and continuous venovenous hemofiltration. *Ther Drug Monit.* 2008;30(1):100-102. doi:10.1097/FTD.0b013e3181633667[PubMed 18223470]

